A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients

This phase II trial is testing a drug called SSGJ-706, alone or in combination with other treatments, in people with advanced non-small cell lung cancer (NSCLC). It is looking for the best dose and checking how well the drug works. **You may be eligible if...** - You are 18 or older with advanced or metastatic NSCLC confirmed by biopsy or lab test - You are in good physical condition (ECOG 0–1) - You are expected to live at least 3 months **You may NOT be eligible if...** - You have active or symptomatic brain metastases - You still have significant side effects from prior cancer treatment (other than hair loss or mild fatigue) - Your organ function (blood, kidney, liver) is inadequate - You are pregnant or breastfeeding - You are allergic to SSGJ-706 Talk to your doctor to see if this trial is right for you.